Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab

• Arnon P. Kater,
• Yanwen Jiang,
• Brenda Chyla,
• John F. Seymour

Affiliations

Arnon P. Kater

Department of Hematology, Amsterdam University Medical Centers, Location AMC, Amsterdam, on behalf of Hovon CLL Working Group, Amsterdam, the Netherlands

Yanwen Jiang

Genentech, Inc., South San Francisco, CA, USA

Brenda Chyla

AbbVie, North Chicago, IL, USA

John F. Seymour

Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia